Canadian Journal of Infectious Diseases and Medical Microbiology
Volume 2022 (2022), Article ID 8332819, 6 pages
https://doi.org/10.1155/2022/8332819

Research Article

Baricitinib for the Management of SARS-CoV-2-Infected Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

Sivananthan Manoharan¹ and Lee Ying Ying²

¹Molecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam 40170, Shah Alam, Selangor, Malaysia
²Asia Metropolitan University, Bandar Baru Seri Alam 81750, Johor Bahru, Johor, Malaysia

Correspondence should be addressed to Sivananthan Manoharan; sivananthan@moh.gov.my

Received 28 March 2022; Accepted 5 July 2022; Published 2 August 2022

Academic Editor: Jayaprakash Kolla

Copyright © 2022 Sivananthan Manoharan and Lee Ying Ying. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Baricitinib is known to reduce mortality and disease progression in COVID-19 patients; however, the data are inconsistent. Therefore, it needs to be explored to further understand the clinical benefits of this drug in the management of COVID-19 patients. Does baricitinib statistically significantly reduce mortality and disease progression in COVID-19 patients? To answer these questions, three databases known as ScienceDirect, PubMed/MEDLINE, and Scopus and other sources, such as preprint (medRxiv) and reference lists, were thoroughly searched. Four randomised controlled trials (RCTs) were included. Based on the meta-analysis, baricitinib statistically significantly reduced mortality with the risk ratio (RR) of RR = 0.74 [95% CI: 0.58 to 0.94; ] and moderately high heterogeneity, where I² = 62% and . On the other hand, RR = 0.84 [95% CI: 0.75 to 0.95; ] with insignificant heterogeneity of I² = 20% and was found for disease progression. Cochrane risk of bias (RoB) analysis revealed that three out of four articles were ranked as high-quality articles with low RoB. Based on the evidence grading, the overall certainty of evidences was moderate. In conclusion, baricitinib statistically significantly reduced mortality and disease progression in COVID-19 patients when the patients were treated with baricitinib at a dosage of 2 mg or 4 mg for a maximum duration of 14 days.

1. Introduction

As of 27th May 2022, more than 530 million people were infected with the novel SARS-CoV-2, which caused COVID-19. More than 6.3 million deaths were recorded, making COVID-19 as one of the deadly diseases in human history [1]. According to Rochelle Walensky, the Director of Centers for Disease Control and Prevention (CDC), the delta strain of SARS-CoV-2/COVID-19 is one of the most infectious respiratory illnesses witnessed by specialists/experts. This strain is very contagious and aggressive compared to other SARS-CoV-2 viral strains [2]. Scientists were looking at several strategies to discover treatments for COVID-19. One of the strategies was to repurpose an anti-rheumatoid arthritis drug (baricitinib) for the management of COVID-19 patients. It is worth citing that on 14 January 2022, the World Health Organization (WHO) strongly endorsed the use of baricitinib with corticosteroids in severe or critical SARS-CoV-2-infected patients. In May 2022, the Food and Drug Administration (FDA) gave full approval to use baricitinib in adult COVID-19 patients and emergency use authorisation (EUA) for children between 2 and 18 years of age [3, 4]. Two research outputs from phase 3 randomised controlled trials (RCTs) led to the current approval of baricitinib by FDA [4]. RCT is regarded as a gold standard study design to explore the efficacy of treatments. When looking at the pyramid of study designs to collect evidence for any treatment effect, RCTs and meta-analyses (MAs) of RCTs are ranked at the highest of the pyramid and produce fairly good evidences. On the other hand, case reports are ranked at the bottom of the pyramid. MA can also be conducted using non-RCT (nRCT)-related evidences. However, MA based on nRCTs provides less strong evidences than MA of RCTs. Observational studies are complementary to RCTs [5]. According to the Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated in February 2022), nRCTs are only included to MA when there are insufficient RCTs to answer the research question [6]. In the current systematic review (SR) and MA, the authors conducted SR and MA based on available RCTs for baricitinib. Despite the recent approvals by WHO and FDA, the outcomes from several RCTs related to baricitinib were conflicting. To the best of the authors’ knowledge, this is the first SR and MA for baricitinib, which involves the inclusion of only RCT evidences. Furthermore, the authors contacted Marconi et al. [7] to acquire more data, especially related to invasive mechanical ventilation (IMV), which could not be found in other articles. In the current study, the nRCTs’ results were not pooled together with RCTs to avoid merging different level of risk of bias (RoB).

2. Methodology

In the present SR and MA, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were referred to build this review. These guidelines were adhered to accordingly. No advanced protocol related to the present SR and MA was developed or registered.

2.1. Research Questions

(1)What is the statistical ability of baricitinib to reduce mortality/death in COVID-19 patients?(2)What is the statistical ability of baricitinib to reduce disease progression in COVID-19 patients?

2.2. Search Strategies, Article Eligibility Criteria, and Data Charting Process

Three main databases, known as PubMed/MEDLINE, ScienceDirect, and Scopus, and other sources, such as preprint (medRxiv) and reference list, were searched thoroughly using keywords, namely, “Randomised controlled trials baricitinib COVID-19; Randomised controlled trials baricitinib SARS-CoV-2 virus; and Randomised controlled trials baricitinib pneumonia.” The searched period was between 2020 and March 2022. The inclusion criteria were as follows:

(i)Patients infected with SARS-CoV-2(ii)Use of baricitinib as the drug for intervention purposes(iii)Presence of proper control/s(iv)Strictly only for RCT studies(v)Clinical efficacy stated in the study outcomes(vi)Only articles in the English language

The data charting activities included screening of titles, abstracts, and texts, which were undertaken completely by two authors, independently.

2.3. Risk of Bias Analysis (RoB) and Grading the Evidence with GRADEpro and Conduct of MA

The Cochrane RoB tool was deployed to measure the quality of RCTs [8]. Furthermore, the authors graded the quality of the articles using GRADEpro Guideline Development Tool software [9]. The MA was carried out using Review Manager 5.4.1 [8]. Dichotomous data type was used. The RCT data were pooled, and relative risk, confidence interval (CI), and Mantel–Haenszel statistical approaches were used. The degree of heterogeneity was assessed based on value, the I² test. Heterogeneity was defined as significant when or I²>50% [10]. A fixed-effect model was used when the data were homogeneous, while a random-effect model was used if the data were heterogeneous. The publication bias (PB) was not checked since only four articles were available. At least ten articles are required to produce a good statistical related funnel plot for detection of PB.

3. Results and Discussion

Based on strict literature search according to the keywords, a total of 52 studies were found and four full RCTs were included for qualitative (SR) and quantitative (MA) analyses (Figure 1). All searched articles could be found in the supplementary file S1. Only four RCTs were available within the search period (up to March 2022); however, the inclusion of more than 10,000 sample size (RCTs’ participants) represented the total population of more than 300 million [11]. In fact, according to Eli Lilly and Company (Lilly), so far about one million patients received baricitinib for the management of COVID-19 in 15 countries [4]. In this scenario, although four RCTs were included, the cumulative sample size, which was more than 10,000 participants, represented a large number of human populations. Table 1 shows the characteristics of the included studies. Except for a study by Horby et al. [12], all other three RCTs were found to be low in RoB. The blinding strategy by Horby et al. [12] was weak due to the open-label study design. Due to the weak blinding strategy, based on the evidence grading through certainty assessments, the overall certainty of the pooled RCTs was moderate (Table 2). Moreover, based on MA for mortality, with the inclusion of 10,815 sample size, baricitinib statistically significantly reduced the mortality in COVID-19 patients with the risk ratio (RR) of RR = 0.74 [95% CI: 0.58 to 0.94; ], but moderate high heterogeneity of I² = 62% and was found (Figure 2(a)). The heterogeneity was suspected to be due to a large sample size by Horby et al. [12]. A large sample size is required to reflect the actual effect of baricitinib in COVID-19 patients. The authors speculated that although it was feasible, it was difficult to conduct blinding strategy when the sample size is extremely large. However, subgroup analysis was not conducted with the inclusion of only low RoB articles due to the fact that the bigger the sample size, the better the detection of actual effect of the drug in COVID-19 patients. Besides, findings by Horby et al. [12] were related to a large sample size (2/3 of total size) and could not be simply excluded. The individual value of RR (0.62–0.91) for all 4 studies supporting baricitinib’s efficacy in reducing mortality in COVID-19 patients.

Figure 1: The flowchart detailing the systematic literature search. The chart was prepared using Review Manager 5.4.1 [8].

Table 1: Characteristics of the included articles and the outcome/s.

Study
Study design and phase
Period of study
Country
Population and age (B vs. C)
Intervention
Comparator
Outcomes
Cochrane RoB

Horby et al. [12]
RCTs-open label and platform trial (factorial design)
Feb 21–Dec 21
1 (UK)
>100 centers/hospitals (58.5 vs. 57.7)
(i) 4 mg baricitinib for 10 days
(ii) Reduced dose in case of low eGFR (<60 mL/min) or patients taking probenecid or in children <9 years old
Usual care
Mortality: reduced
IMV: not reduced
High (due to open-label study design)

Kalil et al. [13]
Full RCTs and phase III trial
May–July 20
8 countries
67 centers (55 vs. 55.8)
(i) Baricitinib 4 mg (maximum 14 days) with remdesivir (maximum 10 days)
(ii) Baricitinib 2 mg (with other health related problems) (maximum 14 days) with remdesivir (maximum 10 days)
Remdesivir
Mortality: not reduced
IMV/ECMO: reduced
Low

Marconi et al. [7]
Full RCTs and phase III trial
Jun 20–Jan 21
12 countries
>100 centers (57.8 vs. 57.5)
(i) Baricitinib 2 mg or 4 mg with matching SOC for maximum 14 days
Placebo with SOC
Mortality: reduced
IMV: not reduced
Low

Ely et al. [14]
Full RCTs and phase III trial
Dec 20–Apr 21
4 countries
18 centers (58.4 vs. 58.8)
(i) Baricitinib 2 mg or 4 mg with SOC for maximum of 14 days
Placebo with SOC
Mortality: reduced
IMV: NA
Low

IMV: invasive mechanical ventilation; SOC: standard of care; B: baricitinib; C: control; RoB: Risk of bias; UK: United Kingdom; eGFR: estimated glomerular filtration rate; ECMO: extracorporeal membrane oxygenation; NA: not available.

Table 2: Grading the evidence with GRADEpro guideline development tool.

Certainty assessment
No. of patients
Effect
Certainty
Importance

No of studies
Study design
Risk of bias
Inconsistency
Indirectness
Imprecision
Other considerations
Baricitinib
Control
Relative (95% CI)
Absolute (95% CI)

Mortality (4 RCTs)

4
Randomised trials
Seriousa
Not serious
Not serious
Not serious
None
619/5478 (11.3%)
712/5337 (13.3%)
RR 0.74 (0.58 to 0.94)
35 fewer per 1,000 (from 56 fewer to 8 fewer)
⊕⊕⊕  ⃝
Moderate
Critical

Disease progression (3 RCTs)

3
Randomised trials
Seriousa
Not serious
Not serious
Not serious
None
454/5239 (8.7%)
528/5113 (10.3%)
RR 0.84 (0.75 to 0.95)
17 fewer per 1,000 (from 26 fewer to 5 fewer)
⊕⊕⊕  ⃝
Moderate
Critical

CI: confidence interval; RR: risk ratio. aOpen-label study [12].

(a)

(b)

Figure 2: (a) The effect of baricitinib on mortality. (b) The effect of baricitinib on disease progression in COVID-19 patients. Marconi et al. [7] were contacted for additional information. The additional information was supplied by Eli Lilly, the sponsor company. The letter is supplied as supplementary file S2.

On the other hand, baricitinib statistically significantly reduced disease progression in COVID-19 patients with RR = 0.84 [95% CI: 0.75 to 0.95; ], but insignificant heterogeneity of I² = 20% and was found (Figure 2(b)). The data related to IMV were used for this analysis because the progression of COVID-19 patients from early/mid-stage to later stage, especially requiring IMV, is regarded as an extremely worsening health condition in COVID-19 patients. King et al. [15] reported that high mortality rate was seen in COVID-19 patients requiring IMV, especially in older patients. According to Goletti and Cantini [16], while remdesivir is appropriate for early stage of COVID-19 management and corticosteroid is fit for the advanced stage of COVID-19 treatment, baricitinib could be utilised in between these two drugs to stop moderately severe COVID-19 patients from encountering the later stage. Due to the importance of IMV data, the authors contacted Marconi et al. [7] to acquire more detailed information mainly related to IMV since this information was not directly available in the article. There was no response from Kalil et al. [13] to gather similar data; therefore, the authors continued with the available IMV/ECMO data. This could serve as a confounding factor; however, it was considered that COVID-19 patients requiring extracorporeal membrane oxygenation (ECMO) were probably lesser than those requiring IMV. This is because ECMO is a costly medical device and probably only available for very limited number of patients. In the current analysis, based on 10,352 sample size, it was proven that baricitinib was able to reduce the disease progression related to IMV in COVID-19 patients. Based on both analyses, baricitinib reduced mortality and disease progression by 13.1% and 14%, respectively.

The advantages of the current MA compared to other MAs indicated the following: (i) large sample size was included to derive concrete outcomes, (ii) only RCT studies were included, (iii) the focus for block disease progression was IMV, (iv) communication was established with one corresponding author to gather more data related to IMV, which was supplied by Lilly, the sponsor company, and (v) GradePro tool was used for grading the evidences, whereby this strategy was lacking in other MAs related to baricitinib. The limitation of the current study was that the result should be interpreted carefully since the heterogeneity was moderately high for mortality. Furthermore, due to the open-label study, performance bias was identified in a study by Horby et al. [12]. This bias could compromise the overall findings, moderately. The authors were unable to exclude this study because the sample size was very large, and more than 99% of the participants were properly followed up. Furthermore, it was considered that this study was probably close to reality due to the broad inclusion criteria, whereby the patients were properly randomised and the outcome data were masked. Understanding this situation, Horby et al. [12] stated that despite the open-label study, the outcomes were clear-cut and were established without bias via linkage to routine health records. Besides, in the article, the authors mentioned that although the participants and study staff were unmasked (open-label/non-blind), the trial committee, investigators, and individuals involved in the study (other than participants and study staff) were masked (blinded) to the trial data outcome.

4. Conclusion

In conclusion, baricitinib statistically significantly reduced mortality and disease progression in COVID-19 patients when the patients were treated at the dosage of 2 mg or 4 mg for a maximum duration of 14 days.

Data Availability

Most of the data for analysis are derived from published articles.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors would like to thank the Director General of Health Malaysia for his permission to publish this article and the Director of the Institute for Medical Research for his support. The open access fee was provided by Institute for Medical Research (IMR), Ministry of Health, Malaysia.

Supplementary Materials

The supplementary files are given separately as supplementary files S1 and S2. (Supplementary Materials)

References

“COVID-19 coronavirus pandemic,” 2022, https://www.worldometers.info/coronavirus/.

R. Mendez, Delta Variant is One of the Most Infectious Respiratory Diseases Known, CDC Director Says, CNBC, Englewood Cliffs, NJ, USA, 2021.

Therapeutics and COVID-19: Living Guideline, World Health Organization, Geneva, Switzerland, 2022.

FDA Approves Lilly and Incyte’s OLUMIANT® (Baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19, Lilly USA, Indianapolis, IN, USA, 2022.

D. C. Grootendorst, K. J. Jager, C. Zoccali, and F. W. Dekker, “Observational studies are complementary to randomized controlled trials,” Nephron Clinical Practice, vol. 114, no. 3, pp. c173–7, 2009.

B. C. Reeves, J. J. Deeks, J. P. T. Higgins et al., “Chapter 24: including non-randomized studies on intervention effects,” Cochrane Handbook for Systematic Reviews of Interventions Version 6.3, John Wiley & Sons, Chichester, UK, 2022.

V. C. Marconi, A. V. Ramanan, S. de Bono et al., “Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-barrier): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial,” Lancet Respiratory Medicine, vol. 9, no. 12, pp. 1407–1418, 2021.

Review Manager (RevMan), “The cochrane collaboration,” 2020, https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.ED000011/full.

G. D. T. GRADEpro, GRADEpro Guideline Development Tool, McMaster University, Hamilton, Canada, 2020.

J. J. Deeks, J. P. Higgins, and D. G. Altman, “Analysing data and undertaking meta-analyses,” Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons, Chichester, UK, pp. 241–284, 2nd edition, 2019.

“Sample size table,” 2022, https://www.research-advisors.com/tools/SampleSize.htm.

P. W. Horby, J. R. Emberson, M. Mafham et al., “Baricitinib in patients admitted to hospital with COVID-19 (recovery): a randomised, controlled, open-label, platform trial and updated meta-analysis,” medRxiv, Article ID 22271623, 2022.

A. C. Kalil, T. F. Patterson, A. K. Mehta et al., “Baricitinib plus remdesivir for hospitalized adults with covid-19,” New England Journal of Medicine, vol. 384, no. 9, pp. 795–807, 2021.

E. W. Ely, A. V. Ramanan, C. E. Kartman et al., “Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial,” Lancet Respiratory Medicine, vol. 10, no. 4, pp. 327–336, 2022.

C. S. King, D. Sahjwani, A. W. Brown et al., “Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure,” PLoS One, vol. 15, no. 11, Article ID e0242651, 2020.

D. Goletti and F. Cantini, “Baricitinib therapy in Covid-19 pneumonia-an unmet need fulfilled,” New England Journal of Medicine, vol. 384, no. 9, pp. 867–869, 2021.